Identification of Prospective Ebola Virus VP35 and VP40 Protein Inhibitors from Myxobacterial Natural Products
Biomolecules · 2024
DOI: 10.3390/biom14060660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Muhammad Hayat und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao 266237, China. Hauptthemen laut MEDLINE: Ebolavirus, Molecular Docking Simulation, Biological Products, Molecular Dynamics Simulation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
The Ebola virus (EBOV) is a lethal pathogen causing hemorrhagic fever syndrome which remains a global health challenge. In the EBOV, two multifunctional proteins, VP35 and VP40, have significant roles in replication, virion assembly, and budding from the cell and have been identified as druggable targets. In this study, we employed in silico methods comprising molecular docking, molecular dynamic simulations, and pharmacological properties to identify prospective drugs for inhibiting VP35 and VP40 proteins from the myxobacterial bioactive natural product repertoire. Cystobactamid 934-2, Cystobactamid 919-1, and Cittilin A bound firmly to VP35. Meanwhile, 2-Hydroxysorangiadenosine, Enhypyrazinone B, and Sorangiadenosine showed strong binding to the matrix protein VP40. Molecular dynamic simulations revealed that, among these compounds, Cystobactamid 919-1 and 2-Hydroxysorangiadenosine had stable interactions with their respective targets. Similarly, molecular mechanics Poisson–Boltzmann surface area (MMPBSA) calculations indicated close-fitting receptor binding with VP35 or VP40. These two compounds also exhibited good pharmacological properties. In conclusion, we identified Cystobactamid 919-1 and 2-Hydroxysorangiadenosine as potential ligands for EBOV that target VP35 and VP40 proteins. These findings signify an essential step in vitro and in vivo to validate their potential for EBOV inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao 266237, China.
- Department of Microbiology, Faculty of Life Sciences and Informatics, Balochistan University of IT, Engineering and Management Sciences, Quetta 87100, Pakistan.
- Shenzhen Research Institute, Shandong University, Shenzhen 518057, China.
- Suzhou Research Institute, Shandong University, Suzhou 215123, China.
ORCID-Profile: Muhammad Rafiq, Yue-Zhong Li
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Guangdong Basic and Applied Basic Research Foundation
- Natural Science Foundation of Jiangsu Province
- Natural Science Foundation of China
Zitieren
APA
Hayat, M., Gao, T., Cao, Y., Rafiq, M., Zhuo, L., & Li, Y. Z. (2024). Identification of Prospective Ebola Virus VP35 and VP40 Protein Inhibitors from Myxobacterial Natural Products. Biomolecules. https://doi.org/10.3390/biom14060660
Vancouver
Hayat M, Gao T, Cao Y, Rafiq M, Zhuo L, Li YZ. Identification of Prospective Ebola Virus VP35 and VP40 Protein Inhibitors from Myxobacterial Natural Products. Biomolecules. 2024. doi:10.3390/biom14060660
BibTeX
@article{Hayat2024,
author = {Hayat, Muhammad and Gao, Tian and Cao, Ying and Rafiq, Muhammad and Zhuo, Li and Li, Yue-Zhong},
title = {Identification of Prospective Ebola Virus VP35 and VP40 Protein Inhibitors from Myxobacterial Natural Products},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14060660}
}
EUVIMED